-
1.发明公开NON-SMALL CELL LUNG CANCER-RELATED GENE, ANLN, AND ITS INTERACTIONS WITH RHOA 有权GEN ANLN与非小细胞肺癌及其与RhoA的相互作用
公开(公告)号：EP1787122A1
公开(公告)日：2007-05-23
申请号：EP05770407.4
申请日：2005-08-09
IPC分类号： G01N33/574
CPC分类号： G01N33/57423 , G01N33/574 , G01N2333/82 , G01N2500/02
摘要： The present invention provides compositions and methods for identifying compounds for treating cancer as well as methods for predicting a prognosis of cancer. In particular, the present invention provides methods and kits for identifying inhibitors of the interaction between ANLN and RhoA which find utility in the treatment and prevention of cancer, particularly lung cancers such as non-small cell lung cancer (NSCLC). Also disclosed herein are compositions for treating or preventing cancer identified by the screening method of the present invention and methods of using same in the treatment and prevention of cancer.
-
公开(公告)号：EP1551998A2
公开(公告)日：2005-07-13
申请号：EP03753941.8
申请日：2003-09-22
CPC分类号： G01N33/57423 , A61K31/7088 , C07K14/47 , C12N15/1135 , C12N2310/11 , C12N2310/14 , C12Q1/6886 , C12Q2600/136 , G01N2800/50
摘要： Disclosed are methods for detecting non-small cell lung cancer using differentially expressed genes. Furthermore, novel human genes whose expression is elevated in non-small cell lung cancer compared to no-cancerous tissues are provided. Also disclosed are methods of identifying compounds for treating and preventing non-small cell lung cancer.
-
3.发明公开
公开(公告)号：EP1853703A2
公开(公告)日：2007-11-14
申请号：EP06714493.1
申请日：2006-02-17
CPC分类号： C12N9/1211 , C12Q1/6886
摘要： The present invention provides peptides comprising the amino acid sequence of SEQ ID NO: 8, 67, 89, as well as peptides comprising the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted, deleted, or added, and having cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing tumors comprising these peptides. The peptides of the present invention can also be used as vaccines.
-
公开(公告)号：EP2606132A1
公开(公告)日：2013-06-26
申请号：EP11817909.2
申请日：2011-08-09
发明人： DAIGO, Yataro , NAKAMURA, Yusuke , TSUNODA, Takuya
IPC分类号： C12N15/09 , A61K48/00 , C07K14/47 , C12N15/113 , C12Q1/68 , G01N33/574
CPC分类号： G01N33/57484 , A61K38/00 , C07K14/4748 , C12N15/113 , C12N2310/14 , C12Q1/6886 , C12Q2600/158 , G01N33/57423 , G01N2500/04
摘要： Objective methods for diagnosing cancer or a predisposition to developing cancer, particularly lung cancer are described herein. The present invention provides a diagnostic method that utilizes the expression level of C6orf167 as an index of cancer. The present invention further provides methods of screening for therapeutic substances useful in the treatment of cancer, e.g. lung cancer. The invention further provides methods of inhibiting the cancer cell growth and either or both of treating and preventing cancer. The invention also features double stranded molecules against C6orf167 gene and an inhibitory polypeptide for NFKBIL2, as well as vector encoding them and compositions containing them.
-
公开(公告)号：EP2350276A1
公开(公告)日：2011-08-03
申请号：EP09809522.7
申请日：2009-08-24
发明人： NAKAMURA, Yusuke , DAIGO, Yataro , TOGASHI, Akira
CPC分类号： C12N15/113 , C12N2310/14 , C12Q1/6886 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158 , G01N33/57423 , G01N2500/10
摘要： The present invention relates to the roles played by the SYNGR4 genes in lung cancer carcinogenesis and features a method for treating or preventing lung cancer by administering a double-stranded molecule against one or more of the SYNGR4 genes or a composition, vector or cell containing such a double stranded molecule and antibody. The present invention also features methods for diagnosing lung cancer or assessing/determining the prognosis of a patient with lung cancer, especially NSCLC or SCLC, using one or more over-expressed genes selected from among SYNGR4. To that end, SYNGR4 may serve as a novel serological biomarker for lung cancer. Also, disclosed are methods of identifying compounds for treating and preventing lung cancer, using as an index their effect on the over-expression of one or more of SYNGR4 in the lung cancer.
-
6.发明授权NON-SMALL CELL LUNG CANCER-RELATED GENE, ANLN, AND ITS INTERACTIONS WITH RhoA 有权GEN ANLN与非小细胞肺癌及其与RhoA的相互作用
公开(公告)号：EP1787122B1
公开(公告)日：2010-10-06
申请号：EP05770407.4
申请日：2005-08-09
IPC分类号： G01N33/574
CPC分类号： G01N33/57423 , G01N33/574 , G01N2333/82 , G01N2500/02
-
公开(公告)号：EP2464749A1
公开(公告)日：2012-06-20
申请号：EP10808083.9
申请日：2010-08-12
发明人： DAIGO, Yataro , NAKAMURA, Yusuke , TSUNODA, Takuya
CPC分类号： C12N15/1135 , C12N15/1137 , C12N2310/14 , C12Q1/6886 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158 , G01N33/57423 , G01N2333/4706 , G01N2500/02
摘要： The present invention is based on the finding that CDC45L gene and PIF1 gene are everexpressed in cancer, and involved in cancer cell survival. The present invention features methods for diagnosing cancer or assessing/determining the prognosis of a subject with cancer, using CDC45L gene and/or PIF1 gene as diagnostic markers. The present invention also features a double-stranded molecule against CDC45L gene or PIF1 gene, a method or composition for treating and/or preventing cancer using such double-stranded molecule Also, disclosed are methods of identifying a candidate compound for treating and preventing lung cancer, using CDC45L and/or PIF1 as molecular targets.
-
8.发明公开EBI3, DLX5, NPTX1 AND CDKN3 FOR TARGET GENES OF LUNG CANCER THERAPY AND DIAGNOSIS 审中-公开EBI3，DLX5，NPTX1和CDKN3肺癌诊断与治疗的靶基因
公开(公告)号：EP2198021A1
公开(公告)日：2010-06-23
申请号：EP08828793.3
申请日：2008-08-21
CPC分类号： A61K31/70 , A61K38/00 , A61K2039/505 , C07K14/4702 , C07K16/22 , C07K16/244 , C07K16/3023 , C07K2317/34 , C07K2317/73 , C07K2317/77 , C12N15/113 , C12N2310/111 , C12N2310/14 , G01N33/57423 , G01N2800/54
摘要： The present invention relates to methods for treating or preventing lung cancer by administering a double-stranded molecule against one or more of EBI3, DLX5, NPTXl, CDKN3 or EF-I delta genes or compositions, vectors or cells containing such a double-stranded molecule. The present invention also features methods for diagnosing lung cancer, especially NSCLC or SCLC, using one or more over-expressed genes selected from among EBI3, DLX5, NPTXl, CDKN3 and/or EF-I delta. Also disclosed are methods of identifying compounds for treating and preventing lung cancer, using as an index their effect on the over-expression of one or more of EBI3, DLX5, CDKN3 and/or EF-I delta in the lung cancer, the cell proliferation function of one or more of EBI3, DLX5, NPTXl, CDKN3 and/or EF-I delta or the interaction between CDKN3 and VRS, EF-I beta, EF-I gamma and/or EF-I delta.
-
9.发明公开IMP-1 ONCOGENE AS A THERAPEUTIC TARGET AND PROGNOSTIC INDICATOR FOR LUNG CANCER 审中-公开IMP-1致癌基因THAN治疗目标及预期指标肺癌
公开(公告)号：EP2059610A1
公开(公告)日：2009-05-20
申请号：EP07805983.9
申请日：2007-08-16
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12N15/1135 , C12N2310/14 , C12Q2600/118 , C12Q2600/136
摘要： IMP-1 was abundantly expressed in the majority of lung-cancers examined. Positive immunostaining of IMP-1 was correlated with tumor size (pT-classification; P=0.0003), non-adenocarcinoma histology (P
-
10.发明授权DKK1 ONCOGENE AS THERAPEUTIC TARGET FOR CANCER AND A DIAGNOSING MARKER 有权DKK1-ONKOGEN ALS治疗ZIELFÜRKREBS UND诊断标记
公开(公告)号：EP2190478B1
公开(公告)日：2016-03-23
申请号：EP08790474.4
申请日：2008-08-21
IPC分类号： C07K16/32 , C12Q1/68 , C07K16/30 , G01N33/574 , A61K39/00
CPC分类号： C07K16/32 , A61K2039/505 , C07K16/3046 , C12Q1/6886 , C12Q2600/136 , C12Q2600/158 , G01N33/574 , G01N2333/4703 , G01N2500/04 , G01N2800/50
-
-
-
-
-
-
-
-
-
搜索结果
32 条记录 (耗时 0.024 秒)
